, Volume 62, Supplement 2, pp 63–70

Pharmacoeconomic Considerations in the Management of Smoking Cessation

Review Article


Smokers are more likely to develop a variety of serious diseases than nonsmokers; the morbidity and mortality from these diseases place a great resource burden on society in respect of demands on healthcare resources and lost productivity.

The cost to the healthcare system of treating the consequences of smoking is high. Given the availability of inexpensive pharmaceutical therapies such as sustained-release bupropion (bupropion SR) and nicotine replacement therapy (NRT), which are proven to be effective, there is economic advantage for governments and the medical profession in encouraging patients to quit. The cost effectiveness of effective smoking cessation support is far superior to that of many other potentially life-saving interventions and, indeed, the UK National Institute for Clinical Excellence (NICE) stated in April 2002 that ‘both bupropion and NRT are considered to be amongst the most effective of all healthcare interventions’. Recent economic analyses have confirmed that the use of bupropion SR as an aid to smoking cessation is a highly cost-effective intervention.


  1. 1.
    US Department of Health and Human Services. Reducing tobacco use: a report of the surgeon general. Atlanta (GA). Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2000Google Scholar
  2. 2.
    NHS Centre for Reviews and Dissemination. Smoking Cessation: what the health service can do. Effectiveness Matters 1998; 3(1): 4Google Scholar
  3. 3.
    The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives. A clinical practice guideline for treating tobacco use and dependence: a US Public Health Service report. JAMA 2000; 283: 3244–54CrossRefGoogle Scholar
  4. 4.
    Lightwood JM, Phibbs CS, Glantz SA. Short-term health and economic benefits of smoking cessation: low birth weight. Pediatrics 1999; 104(6): 1312–20PubMedCrossRefGoogle Scholar
  5. 5.
    Lightwood JM, Glantz SA. Short-term economic and health benefits of smoking cessation: myocardial infarction and stroke. Circulation 1997; 96: 1089–96PubMedCrossRefGoogle Scholar
  6. 6.
    World Bank. Curbing the epidemic: governments and the economics of tobacco control [report]. Washington (DC): World Bank, 1999Google Scholar
  7. 7.
    US Public Health Service. Treating tobacco use and dependence. US Public Health Service, 2000Google Scholar
  8. 8.
    Bartlett JC, Miller LS, Rice DP, et al. Medical-care expenditures attributable to cigarette smoking -United States. 1993 Morb Mortal Wkly Rep 1994; 43(26): 469–72Google Scholar
  9. 9.
    Miller LS, Zhang X, Rice DP, et al. State estimates of total medical expenditures attributable to cigarette smoking, 1993 [abstract]. Public Health Rep 1998; 113: 447–58PubMedGoogle Scholar
  10. 10.
    Miller VP, Ernst C, Collin F. Smoking: attributable medical care costs in the USA. Soc Sci Med 1999; 48(3): 375–91PubMedCrossRefGoogle Scholar
  11. 11.
    Buck D, Godfrey C, Parrott S. Cost effectiveness of smoking cessation interventions. London: Health Education Authority, 1997Google Scholar
  12. 12.
    Buck D, Godfrey C. Helping smokers give up: guidance for purchasers on cost-effectiveness. London: Health Education Authority, 1994Google Scholar
  13. 13.
    Collins D, Lapsley HM. The economic costs generated by tobacco use in Australia. Department of Human Services and Health submission to the Industry Commission Inquiry into the tobacco growing and manufacturing industries. Canberra: Commonwealth Department of Human Services and Health, 1994Google Scholar
  14. 14.
    Kaiserman MJ. The cost of smoking in Canada, 1991. Chronic Dis Can 1997; 18: 13–9PubMedGoogle Scholar
  15. 15.
    Jin SG, Lu BY, Yan DY, et al. An evaluation on smoking-induced health costs in China (1988–1989). Biomed Environ Sci 1995; 8: 342–9PubMedGoogle Scholar
  16. 16.
    Parrott S, Godfrey C, Raw M, et al. Guidance for commissioners on the cost effectiveness of smoking cessation interventions. Health Educational Authority. Thorax 1998; 53 Suppl 5 (Pt 2): S1–38PubMedCrossRefGoogle Scholar
  17. 17.
    Ruff L, Volmer T, Novak D, et al. The economic impact of smoking in Germany. Eur Respir J 2000; 16: 385–90PubMedCrossRefGoogle Scholar
  18. 18.
    Phillips D, Kawachi I, Tilyard M. The economics of smoking: an overview of the international and New Zealand literature. Pharmacoeconomics 1993; 3: 462–70PubMedCrossRefGoogle Scholar
  19. 19.
    Sanner T. What does cigarette smoking cost society?. [in Norwegian]. Tidsskr Nor Laegeforen 1991; 111(28): 3420–2PubMedGoogle Scholar
  20. 20.
    Buck D. The cost-effectiveness of smoking cessation interventions: what do we know? Int J Health Educ 1997; 35: 44–52Google Scholar
  21. 21.
    Centers for Disease Control and Prevention. Medical-care expenditures attributable to cigarette smoking: United States, 1993. Morb Mortal Wkly Rep 1994; 43: 469–72Google Scholar
  22. 22.
    Warner KE, Hodgson TA, Carroll CE. Medical costs of smoking in the United States: estimates, their validity, and their implications. Tob Control 1999; 8(3): 290–300PubMedCrossRefGoogle Scholar
  23. 23.
    Buck D, Godfrey C, Raw M, et al. Tobacco and jobs: the impact of reducing consumption on employment in the UK. York: Society for the Study of Addiction, Centre for Health Economics, 1995Google Scholar
  24. 24.
    Drever F, Whitehead M, editors. Health inequalities: decennial supplement: Office for National Statistics. London: The Stationery Office, 1997. Series DS: no. 15Google Scholar
  25. 25.
    Office for National Statistics. Living in Britain: results from the 1998 general household survey. London: The Stationery Office, 2000Google Scholar
  26. 26.
    Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340: 685–91PubMedCrossRefGoogle Scholar
  27. 27.
    World Health Organization. International statistical classification of diseases and related health problems (ICD-10). 10th rev, vol 1. Geneva: World Health Organization, 1992Google Scholar
  28. 28.
    West R, McNeill A, Raw M. Smoking cessation guidelines for health professionals: an update. Thorax 2000; 55: 987–99PubMedCrossRefGoogle Scholar
  29. 29.
    Tengs TO, Adams ME, Pliskin JS, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 1995; 15(3): 369–90PubMedCrossRefGoogle Scholar
  30. 30.
    Warner KE. Cost-effectiveness of nicotine replacement therapy. Proceedings of Future Directions in Nicotine Replacement Therapy meeting; 1993 Oct; Paris. Chester (UK): Adis International, 1993: 35–40Google Scholar
  31. 31.
    Warner KE. Cost effectiveness of smoking-cessation therapies: interpretation of the evidence and implications for coverage. Pharmacoeconomics 1997; 11(6): 538–49PubMedCrossRefGoogle Scholar
  32. 32.
    Cromwell J, Bartosch WJ, Fiore MC, et al. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy and Research. JAMA 1997; 278(21): 1759–66PubMedCrossRefGoogle Scholar
  33. 33.
    Stapleton JA, Lowin A, Russell MAH. Prescription of transdermal nicotine patches for smoking cessation in general practice: evaluation of cost-effectiveness. Lancet 1999; 354: 208–13CrossRefGoogle Scholar
  34. 34.
    Wasley MA, McNagny SE, Phillips VL, et al. The cost-effectiveness of the nicotine transdermal patch for smoking cessation. Prev Med 1997; 26: 264–70PubMedCrossRefGoogle Scholar
  35. 35.
    Halpern MT, Khan ZM, Young TL, et al. Economic model of sustained-release bupropion hydrochloride in health plan and work site smoking-cessation programs. Am J Health Syst Pharm 2000; 57: 1421–9PubMedGoogle Scholar
  36. 36.
    Nielsen K, Fiore MC. Cost-benefit analysis of sustained-release bupropion, nicotine patch, or both for smoking cessation. Prev Med 2000; 30: 209–16PubMedCrossRefGoogle Scholar
  37. 37.
    Woolacott N, Jones L, Forbes C, et al. A rapid and systematic review of the clinical and cost effectiveness of bupropion SR and nicotine replacement therapy (NRT) for smoking cessation. Available from URL: http://www.nice.org.uk/Docref.asp?d=30634 [Accessed 2002 Apr 11]
  38. 38.
    Musin A, Perez I, Anton E, et al. Impact of Zyntabac on morbidity, mortality and health care costs due to smoking in Spain [abstract]. 8th Annual Meeting of the Society for Research on Nicotine and Tobacco; 2002 Feb 20–23; Savannah (GA)Google Scholar
  39. 39.
    Britton J, Bates C, Channer K, et al. The management of nicotine addiction: nicotine addiction in Britain. London: Royal College of Physicians of London, 2000Google Scholar
  40. 40.
    Eddy DM. David Eddy ranks the tests. Harv Health Lett 1992; 17(9): 10–11Google Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  1. 1.Department of Health Sciences & Centre for Health Economics, Alcuin College Teaching BuildingUniversity of YorkYorkUK
  2. 2.University of OxfordOxfordUK

Personalised recommendations